{Magrolimab | This innovative agent represents a significant advance in malignant immunotherapy due to the distinctive mode of effect.{ It | This strategy disrupts a “don’t eat me” signal, facilitated by this CD47 surface marker – this essential driver of macrophage consumption – allowing immune cells to easily remove tumor masses. Initia